FOSPET predicts VA

Article

Foveal outer segment/pigment epithelial thickness (FOSPET) is significantly thinner in patients with retinitis pigmentosa (RP) than in normal eyes and also shows correlation in logMAR visual acuity (VA), indicating it may be a predictor of VA in RP, according to a study published in the December 2006 issue of the American Journal of Ophthalmology.

Foveal outer segment/pigment epithelial thickness (FOSPET) is significantly thinner in patients with retinitis pigmentosa (RP) than in normal eyes and also shows correlation in logMAR visual acuity (VA), indicating it may be a predictor of VA in RP, according to a study published in the December 2006 issue of the American Journal of Ophthalmology.

Andre Witkin, MD from the New England Eye Center, Boston, USA and colleagues, conducted an observational case series of nine eyes of nine patients with RP and related diseases which were imaged using ultra-high resolution optical coherence tomography (UHR-OCT). Concurrently, 36 eyes of 36 normal subjects were also imaged this way. Central foveal thickness (CFT) and FOSPET were defined and measured on UHR-OCT images in all subjects and were compared between the two groups using unpaired t tests. The two thickness measurements in RP subjects were correlated with VA using Pearson correlation and linear regression.

The UHR-OCT images showed macular photoreceptor thinning in all RP subjects. The difference in CFT between the two groups was not statistically significant (p=0.103), however the difference in FOSPET was (p=0.003). VA showed some correlation with CFT (Pearson r=0.43, r2=0.187, p=0.245) and a strong correlation with FOSPET (Pearson r=0.942, r2=0.887, p<0.0001).

The researchers believe that FOSPET may represent a possible predictor of VA in patients with RP.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.